Since then, several ICIs have been approved for cancer therapy, including the anti-PD-1 MAbs nivolumab, pembrolizumab, and cemiplimab, and the anti-PD-L1 MAbs atezolizumab, avelumab, and durvalumab [145], whereas the discovery of CTLA-4 and PD-1 blockade by James P. Allison and Tasuku Honjo, respectively, led them to the Nobel-Prize in 2018 [146]. Here, CTLA4 is linked to cancer.